Compounds > ecomustine
Page last updated: 2024-11-11

ecomustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ecomustine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9883222
CHEMBL ID2106341
SCHEMBL ID60616
MeSH IDM0162901

Synonyms (23)

Synonym
nsc-609224
nsc 609224
brn 6487760
ecomustina [inn-spanish]
methyl 3-(3-(2-chloroethyl)-3-nitrosoureido)-2,3-dideoxy-alpha-d-arabino-hexapyranoside
ecomustinum [inn-latin]
ecomustine
ecomustine [inn]
alpha-d-arabino-hexopyranoside, methyl 3-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-2,3-dideoxy-
methyl 3-(3-(2-chloroethyl)-3-nitrosoureido)-2,3-dideoxy-alpha-d-arabino-hexopyranoside
98383-18-7
unii-7369r4j7s2
7369r4j7s2 ,
ecomustinum
CHEMBL2106341
SCHEMBL60616
1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea
Q27266144
alpha-d-arabino-hexopyranoside, methyl 3-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2,3-dideoxy-
1-(2-chloroethyl)-3-((2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxytetrahydro-2h-pyran-4-yl)-1-nitrosourea
AKOS040746790
HY-113743
CS-0063106
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID121628Anti tumor activity l when treated to mice with B16 Melanocarcinoma with 10 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121434The number of B16 melanocarcinoma mice survived after 60 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 3/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230865Mortality range of the mice with B16 Melanocarcinoma treated with 30 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231019Mortality range of the mice with L1210 leukemia treated with 10 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124878Median survival time of the non surviving mice; treated with 5 mg/kg of compound to mice with L1210 leukemia; 11-321989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230863Mortality range of the mice with B16 Melanocarcinoma treated with 10 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117576The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 10 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121560The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 10 mg/kg intraperitoneally; 8/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117578The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 5 mg/kg intraperitoneally; 8/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231020Mortality range of the mice with L1210 leukemia treated with 2.5 mg/kg of dose intra peritoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121578The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 0.625 mg/kg intraperitoneally; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231023Mortality range of the mice with L1210 leukemia treated with 30 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 1/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121582The number of Lewis lung mice survived after 30 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 20/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230869Mortality range of the mice with L1210 leukemia treated with 1.25 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121751Anti tumor activity l when treated to mice with B16 Melanocarcinoma with 5 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121576The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 5 mg/kg intraperitoneally; 2/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID229830Ratio of mice died to that of mice treated with 20 mg/kg of compound in olive oil intraperitoneally with Lewis lung; 0/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID229832Ratio of mice died to that of mice treated with 5 mg/kg of compound in aqueous solution intraperitoneally with L1210 leukemia; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124877Median survival time of the non surviving mice; treated with 5 mg/kg of compound to mice with B16 Melanocarcinoma; 30-471989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121422The number of B16 Melanocarcinoma mice survived after 30 days with compound injected by a dose of 20 mg/kg intraperitoneally; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117569The number of B16 Melanocarcinoma mice survived after 30 days with compound injected by a dose of 5 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230868Mortality range of the mice with L1210 leukemia treated with 0.625 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID137957The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 10 mg/kg intra peritoneally; 8/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124741Median survival time of the non surviving mice; There is a single death on day 221989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117572The number of B16 melanocarcinoma mice survived after 30 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 13/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231018Mortality range of the mice with L1210 leukemia treated with 10 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117215Lethal dose was evaluated in male mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230866Mortality range of the mice with B16 Melanocarcinoma treated with 5 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121565The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 30 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID119127Median survival time of the non surviving mice; treated with 20 mg/kg of compound in olive oil to mice with L1210 leukemia tumor; 33-571989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121575The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 30 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121561The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 10 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121584The number of Lewis lung mice survived after 60 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 18/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121754Anti tumor activity l when treated to mice with L1210 leukemia with 2.5 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121436The number of L1210 Leukemia mice survived after 30 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 15/151989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID137955The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 1.25 mg/kg intraperitoneally; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231021Mortality range of the mice with L1210 leukemia treated with 2.5 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121573The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 2.5 mg/kg intraperitoneally; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID137956The number of L1210 Leukemia mice survived after 60 days with compound in olive oil injected by a dose of 20 mg/kg intraperitoneally; 7/151989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121752Anti tumor activity l when treated to mice with L1210 leukemia with 0.625 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID119122Median survival time of the non surviving mice; treated with 20 mg/kg of compound in olive oil to mice with B16 Melanocarcinoma; 12-471989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124872Median survival time of the non surviving mice; treated with 10 mg/kg of compound to mice with B16 Melanocarcinoma; 34-471989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117575The number of L1210 leukemia mice survived after 60 days with compound in aqueous solution injected by a dose of 20 mg/kg intraperitoneally; 6/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121426The number of B16 Melanocarcinoma mice survived after 30 days with compound injected by a dose of 10 mg/kg intraperitoneally; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117568The number of L1210 leukemia mice survived after 30 days with compound in aqueous solution injected by a dose of 20 mg/kg intraperitoneally; 6/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231024Mortality range of the mice with L1210 leukemia treated with 5 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117574The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 5 mg/kg intraperitoneally; 3/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117255Lethal dose was evaluated in male mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121562The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 2.5 mg/kg intraperitoneally; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID230864Mortality range of the mice with B16 Melanocarcinoma treated with 20 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121753Anti tumor activity l when treated to mice with L1210 leukemia with 1.25 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID119119Median survival time of the non surviving mice; Two deaths one on dat 37 and other on day D511989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124881There is a single death on day 411989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121425The number of B16 Melanocarcinoma mice survived after 60 days with compound injected by a dose of 5 mg/kg intraperitoneally; 1/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117577The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 20 mg/kg intraperitoneally; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID116710Lethal dose was evaluated in male mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117571The number of B16 Melanocarcinoma mice survived after 60 days with compound injected by a dose of 10 mg/kg intraperitoneally; 3/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121567The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 5 mg/kg intraperitoneally; 8/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID229829Ratio of mice died to that of mice treated with 20 mg/kg of compound in olive oil intraperitoneally with L1210 leukemia tumor; 0/151989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID134225Lethal dose was evaluated in female mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124870Median survival time of the non surviving mice; treated with 1.25 mg/kg of compound to mice with L1210 leukemia; 16-191989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121621Anti tumor activity in olive oil when treated to mice with B16 melanocarcinoma with 20 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231022Mortality range of the mice with L1210 leukemia treated with 20 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117573The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 2.5 mg/kg intraperitoneally; 8/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124874Median survival time of the non surviving mice; treated with 2.5 mg/kg of compound to mice with L1210 leukemia; 11-141989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121424The number of B16 Melanocarcinoma mice survived after 60 days with compound injected by a dose of 30 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117214Lethal dose was evaluated in female mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124867Median survival time of the non surviving mice; treated with 0.625 mg/kg of compound to mice with L1210 leukemia; 10-121989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID124876Median survival time of the non surviving mice; treated with 2.5 mg/kg of compound to mice with L1210 leukemia; 40-541989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121755Anti tumor activity l when treated to mice with L1210 leukemia with 5 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID119118Median survival time of the non surviving mice; There are four deaths each on day 18, day 20, day 211989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID229831Ratio of mice died to that of mice treated with 20 mg/kg of compound in olive oil intraperitoneally with B16 Melanocarcinoma; 0/201989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121423The number of B16 Melanocarcinoma mice survived after 30 days with compound injected by a dose of 30 mg/kg intraperitoneally; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117570The number of B16 Melanocarcinoma mice survived after 60 days with compound injected by a dose of 20 mg/kg intraperitoneally; 9/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121564The number of L1210 leukemia mice survived after 30 days with compound injected by a dose of 20 mg/kg intraperitoneally; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID231025Mortality range of the mice with L1210 leukemia treated with 5 mg/kg of dose intraperitoneally with no of mice survived/no of mice treated; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121624Anti tumor activity in olive oil when treated to mice with L1210 leukemia with 20 mg/kg dose of compound intraperitoneally was expressed as percent of treated to control (T/C %)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID117254Lethal dose was evaluated in female mouse1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
AID121574The number of L1210 leukemia mice survived after 60 days with compound injected by a dose of 2.5 mg/kg intraperitoneally; 0/81989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
taurine
[no description available]		1.9710amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.3820N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9710
B16 Melanoma
[description not available]		02.3820
Experimental Neoplasms
[description not available]		01.9710
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Cancer of Colon
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9710